Antibiotic treatment for the sexual partners of women with bacterial vaginosis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 5, 2015, Pages

  Amaya Guio, Jairo ^a   Martinez Velasquez, Mercy Yolima ^b   Viveros Carreño, David Andres ^a   Sierra Barrios, Eloisa Mercedes ^a   Grillo Ardila, Carlos F ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b Saludcoop EPS Obstetric and Gynaecology Ultrasound Department   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84989248647     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011701     Document Type: Article

References (49)

1. Amit A, Rawat DS, Rawat MSM. 5-Nitroimidazole derivatives: a scope of modification for medicinal chemists. Research Journal of Chemical Science 2013;3(7):104-13.
2. Angel-Müller E, Rodríguez A, Núñez-Forero LM, Moyano LF, González P, Osorio E, et al. The prevalence of and factors associated with C. trachomatis, N. gonorrheae, T. vaginalis, C. albicans infection, syphilis, HIV and bacterial vaginosis in females suffering lower genital tract infection symptoms in three healthcare attention sites in Bogotá, Colombia, 2010. Rev. Colomb. Obstet. Ginecol. 2010;63(1):25-35.
3. Bilardi JE, Walker S, Temple-Smith M, McNair R, Mooney-Somers J, Bellhouse C, et al. The burden of bacterial vaginosis: women's experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One 2013;8(9):e74378.
4. Bouazza N, Pestre V, Jullien V, Curis E, Urien S, Salmon D, et al. Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. British Journal of Clinical Pharmacology 2012;74(6):971-7.
5. Bradshaw CS, Morton AN, Garland SM, Morris MB, Moss LM, Fairley CK. Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstetrics and Gynecology 2005;106(1):105-14. [PUBMED: 15994624]
6. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. The Journal of Infectious Diseases 2006;193(11):1478-86. [PUBMED: 16652274]
7. Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD000262]
8. Brotman RM. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. The Journal of Clinical Investigation 2011;121(12):4610-7.
9. Brunton LL, Chabner BA, Knollman BC, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th Edition. New York, NY: McGraw-Hill Companies Inc., 2011.
10. Bukusi E, Thomas KK, Nguti R, Cohen CR, Weiss N, Coombs RW, et al. Topical penile microbicide use by men to prevent recurrent bacterial vaginosis in sex partners: a randomized clinical trial. Sexually Transmitted Diseases 2011;38(6):483-9. [PUBMED: 22256334]
11. Chavez N, Molina H, Sánchez J, Gelaye B, Sánchez SE. Douches and other risks of bacterial vaginosis [Duchas vaginales y otros riesgos de vaginosis bacteriana]. Revista Peruana de Medicina Experimental y Salud Pública. 2009;26(3):299-306. [PUBMED: 21132048]
12. Colli E, Landoni M, Parazzini F. Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial. Genitourinary Medicine 1997;73(4):267-70.
13. Derby LE, Jick H, Henry DA, Dean AD. Erythromycin-associated cholestatic hepatitis. The Medical Journal of Australia 1993;158(9):600-2.
14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
15. Fethers KA, Fairley CK, Hocking JS, Gurrin LC, Bradshaw CS. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clinical Infectious Diseases 2008;47(11):1426-35. [PUBMED: 18947329]
16. Fethers KA, Fairley CK, Morton A, Hocking JS, Hopkins C, Kennedy LJ, et al. Early sexual experiences and risk factors for bacterial vaginosis. The Journal of Infectious Diseases 2009;200(11):1662-70. [PUBMED: 19863439]
17. Flaherty JF Jr, Gatti G, White J, Bubp J, Borin M, Gambertoglio JG. Protein binding of clindamycin in sera of patients with AIDS. Antimicrobial Agents and Chemotherapy 1996;40(5):1134-8.
18. Gatti G, Flaherty J, Bubp J, White J, Borin M, Gambertoglio J. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrobial Agents and Chemotherapy 1993;37(5):1137-43.
19. Gillet E, Meys JF, Verstraelen H, Verhelst R, De Sutter P, Temmerman M, et al. Association between bacterial vaginosis and cervical intraepithelial neoplasia: systematic review and meta-analysis. PLoS One 2012;7(10):e45201.
20. Goldenberg RL, Culhane JF, Johnson DC. Maternal infection and adverse fetal and neonatal outcomes. Clinics in Perinatology 2005;32(3):523-59.
21. Gurwith MJ, Rabin HR, Love K. Diarrhea associated with clindamycin and ampicillin therapy: preliminary results of a cooperative study. The Journal of Infectious Diseases 1977;135(Suppl):S104-10.
22. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443-57.
23. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
24. Josefsson K, Bergan T, Magni L. Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base. British Journal of Clinical Pharmacology 1982;13(5):685-91.
25. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. American Journal of Obstetrics and Gynecology 2013;209(6):505-23.
26. Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clinical Pharmacokinetics 1999;36(5):353-73.
27. Madhivanan P, Barreto GA, Revawala A, Anderson C, McKinney S, Pierre-Victor D. Where are we with partner treatment in bacterial vaginosis? A critical appraisal of the latest systematic review. Sexually Transmitted Diseases 2013;40(6):518.
28. Mandar R. Microbiota of male genital tract: Impact on the health of man and his partner. Pharmacological Research. 2013;69(1):32- 41. [PUBMED: 23142212]
29. Marrazzo JM. Interpreting the epidemiology and natural history of bacterial vaginosis: are we still confused?. Anaerobe 2011;17(4):186-90.
30. Marrazzo J, Coffey P, Bingham A. Sexual practices, risk perception and knowledge of sexually transmitted disease risk among lesbian and bisexual women. Perspectives on Sexual and Reproductive Health 2005;37(1):6-12. [PUBMED: 15888397]
31. Mehta SD. Response to Madhivanan et al. Sexually Transmitted Diseases 2013;40(6):518-9.
32. Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women. Sexually Transmitted Diseases 2012;39(10):822-30.
33. Ministerio de Salud y Protección Social - Colciencias. Clinical Practice Guidelines for the syndromic approach to the diagnosis and treatment of patients with sexually transmitted infections and other genital tract infections. Guide 16. [Guia de practica clinica para el manejo sindromico de los pacientes con infecciones de transmision sexual y otras infecciones del tracto genital - 2013]. http://gpc.minsalud.gov.co/Documents/Guias-PDF-Recursos/ITS/GPC_Comple_ITS.pdf. April 2013.
34. Mirmonsef P, Krass L, Landay A, Spear GT. The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Current HIV Research 2012;10(3):202-10.
35. Morris MC, Rogers PA, Kinghorn GR. Is bacterial vaginosis a sexually transmitted infection?. Sexually Transmitted Infections 2001;77(1):63-8. [PUBMED: 11158694]
36. Mylonas I, Bergauer F. Diagnosis of vaginal discharge by wet mount microscopy: a simple and underrated method. Obstetrical & Gynecological Survey 2011;66(6):359-68.
37. Nelson DE, Dong Q, Van der Pol B, Toh E, Fan B, Katz BP, et al. Bacterial communities of the coronal sulcus and distal urethra of adolescent males. PLoS One 2012;7(5):e36298. [PUBMED: 22606251]
38. Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD006055]
39. Oleen-Burkey MA, Hillier SL. Pregnancy complications associated with bacterial vaginosis and their estimated costs. Infectious Diseases in Obstetrics and Gynecology 1995;3(4):149-57.
40. Potter J. Should sexual partners of women with bacterial vaginosis receive treatment?. The British Journal of General Practice 1999;49(448):913-8.
41. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
42. Sangkomkamhang US, Lumbiganon P, Prasertcharoensook W, Laopaiboon M. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD006178]
43. Smart S, Singal A, Mindel A. Social and sexual risk factors for bacterial vaginosis. Sexually Transmitted Infections 2004;80(1):58-62.
44. Taylor BD, Darville T, Haggerty CL. Does bacterial vaginosis cause pelvic inflammatory disease?. Sexually Transmitted Diseases 2013;40(2):117-22.
45. Trevor AJ, Katzung BG, Kruidering-Hall M, Masters SB. Katzung & Trevor's Pharmacology Examination and Board Review. 10th Edition. New York, NY: McGraw-Hill Companies Inc., 2012.
46. Workowski K, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recommendations and Reports 2010;59(RR-12):1-110.
47. Wynalda MA, Hutzler JM, Koets MD, Podoll T, Wienkers LC. In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metabolism and Disposition 2003;31(7):878-87.
48. Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, Ekins S, et al. A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metabolism and Disposition 2008;36(8):1689-97.
49. Zuckerman JM, Qamar F, Bono BR. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). The Medical Clinics of North America 2011;95(4):761-91.